Clinical Trial Update: GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating GMEB-SASS, a gene-modified skin substitute, for treating recessive dystrophic epidermolysis bullosa, is currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Recessive Dystrophic Epidermolysis Bullosa

Drugs mentioned

• GMEB-SASS

Snippet

Sponsor: CHU de Quebec-Universite Laval | Conditions: RDEB, Recessive Dystrophic Epidermolysis Bullosa | Phase 1, Phase 2 | Status: RECRUITING